Celltrion Pharm, 2Q Sales of 98.7 Billion KRW and Operating Profit of 16.6 Billion KRW Recorded

Celltrion Pharm CI (Photo by Celltrion Pharm)

[Asia Economy Reporter Chunhee Lee] Celltrion Pharm reported sales of 98.7 billion KRW and operating profit of 16.6 billion KRW in the second quarter of this year. Sales increased by 112.8% and operating profit rose by 189.3% compared to the same period last year.

On the 17th, Celltrion Pharm announced that based on the second quarter financial statements, it recorded sales of 98.74427 billion KRW, operating profit of 16.62836 billion KRW, and net profit of 13.23703 billion KRW. These figures represent growth of 112.8% in sales, 189.3% in operating profit, and 239.9% in net profit compared to the same period last year.

A Celltrion Pharm official explained, "Following the previous quarter, we achieved strong performance with balanced growth across all business sectors of chemical pharmaceuticals and biopharmaceuticals."

In the biopharmaceutical sector, three antibody biosimilars (biopharmaceutical generics) ? the autoimmune treatment ‘Remsima’, the blood cancer treatment ‘Truxima’, and the breast and stomach cancer treatment ‘Herzuma’ ? recorded sales exceeding 12.2 billion KRW, showing approximately 30% growth compared to the same period last year.

This content was produced with the assistance of AI translation services.